|
1
|
McPherson K, Steel CM and Dixon JM: Breast
cancer-epidemiology, risk factors, and genetics. BMJ. 321:624–628.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolff AC, Hammond ME, Schwartz JN, et al:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar
|
|
4
|
Akiyama T, Sudo C, Ogawara H, et al: The
product of the c-erbB-2 gene: a 185-kilodalton glycoprotein with
tyrosine kinase activity. Science. 232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dal Lago L, Durbecq V, Desmedt C, et al:
Correction for chromosome-17 is critical for the determination of
true Her-2/neu gene amplification status in breast cancer. Mol
Cancer Ther. 5:2572–2579. 2006.PubMed/NCBI
|
|
6
|
Ma Y, Lespagnard L, Durbecq V, et al:
Polysomy 17 in HER-2/neu status elaboration in breast cancer:
effect on daily practice. Clin Cancer Res. 11:4393–4399. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reddy JC, Reimann JD, Anderson SM and
Klein PM: Concordance between central and local laboratory HER2
testing from a community-based clinical study. Clin Breast Cancer.
7:153–157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reinholz MM, Bruzek AK, Visscher DW, et
al: Breast cancer and aneusomy 17: implications for carcinogenesis
and therapeutic response. Lancet Oncol. 10:267–277. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang W and Yu Y: The important molecular
markers on chromosome 17 and their clinical impact in breast
cancer. Int J Mol Sci. 12:5672–5683. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Downs-Kelly E, Yoder BJ, Stoler M, et al:
The influence of polysomy 17 on HER2 gene and protein expression in
adenocarcinoma of the breast: a fluorescent in situ hybridization,
immunohistochemical, and isotopic mRNA in situ hybridization study.
Am J Surg Pathol. 29:1221–1227. 2005. View Article : Google Scholar
|
|
11
|
Bose S, Mohammed M, Shintaku P and Rao PN:
Her-2/neu gene amplification in low to moderately expressing breast
cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast
J. 7:337–344. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Farabegoli F, Ceccarelli C, Santini D, et
al: c-erbB-2 over-expression in amplified and non-amplified breast
carcinoma samples. Int J Cancer. 84:273–277. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pritchard KI, Munro A, O’Malley FP, et al:
Chromosome 17 centromere (CEP17) duplication as a predictor of
anthracycline response: evidence from the NCIC Clinical Trials
Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat. 131:541–551.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lal P, Salazar PA, Ladanyi M and Chen B:
Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast
carcinomas without HER-2/neu gene amplification. J Mol Diagn.
5:155–159. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Varshney D, Zhou YY, Geller SA and Alsabeh
R: Determination of HER-2 status and chromosome 17 polysomy in
breast carcinomas comparing HercepTest and PathVysion FISH assay.
Am J Clin Pathol. 121:70–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosenberg CL: Polysomy 17 and HER-2
amplification: true, true, and unrelated. J Clin Oncol.
26:4856–4858. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vanden Bempt I, Van Loo P, Drijkoningen M,
et al: Polysomy 17 in breast cancer: clinicopathologic significance
and impact on HER-2 testing. J Clin Oncol. 26:4869–4874.
2008.PubMed/NCBI
|
|
18
|
Jiang HY, Zhang SQ and Zhao T: A new
method to make nuclei or cell microarrays. Diagn Mol Pathol.
15:109–114. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tse CH, Hwang HC, Goldstein LC, et al:
Determining true HER2 gene status in breast cancers with polysomy
by using alternative chromosome 17 reference genes: implications
for anti-HER2 targeted therapy. J Clin Oncol. 29:4168–4174. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li X, Wan L, Shen H, et al: Thyroid
transcription factor-1 amplification and expressions in lung
adenocarcinoma tissues and pleural effusions predict patient
survival and prognosis. J Thorac Oncol. 7:76–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Birner P, Oberhuber G, Stani J, et al:
Evaluation of the United States Food and Drug
Administration-approved scoring and test system of HER-2 protein
expression in breast cancer. Clin Cancer Res. 7:1669–1675.
2001.PubMed/NCBI
|
|
22
|
Watters AD, Going JJ, Cooke TG and
Bartlett JM: Chromosome 17 aneusomy is associated with poor
prognostic factors in invasive breast carcinoma. Breast Cancer Res
Treat. 77:109–114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Risio M, Casorzo L, Redana S and
Montemurro F: HER2 gene-amplified breast cancers with monosomy of
chromosome 17 are poorly responsive to trastuzumab-based treatment.
Oncol Rep. 13:305–309. 2005.PubMed/NCBI
|
|
24
|
Hammock L, Lewis M, Phillips C and Cohen
C: Strong HER-2/neu protein overexpression by immunohistochemistry
often does not predict oncogene amplification by fluorescence in
situ hybridization. Hum Pathol. 34:1043–1047. 2003.
|
|
25
|
Pritchard KI, Shepherd LE, O’Malley FP, et
al: HER2 and responsiveness of breast cancer to adjuvant
chemotherapy. N Engl J Med. 354:2103–2111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ejlertsen B, Jensen MB, Nielsen KV, et al:
HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant
anthracycline-containing chemotherapy in high-risk breast cancer
patients. J Clin Oncol. 28:984–990. 2010. View Article : Google Scholar : PubMed/NCBI
|
